All > Pancreatic Cancer > Ovarian Cancer

TRPV6 Calcium Channel Inhibitor SOR-C13 for Stage IVA Prostate Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Stage IVA Prostate Cancer+22 MoreTRPV6 Calcium Channel Inhibitor SOR-C13 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This study is evaluating whether a drug may help treat cancer.

Eligible Conditions
  • Stage IVA Prostate Cancer
  • Stage IVA Ovarian Cancer
  • Stage IV Pancreatic Cancer
  • Refractory Malignant Solid Tumor
  • Stage III Ovarian Cancer
  • Stage IVB Prostate Cancer
  • Stage IVB Ovarian Cancer
  • Stage III Prostate Cancer
  • Stage IIB Pancreatic Cancer
  • Stage IV Ovarian Cancer
  • Stage II Pancreatic Cancer
  • Stage III Pancreatic Cancer
  • Stage IIIA Ovarian Cancer
  • Stage IIIB Prostate Cancer
  • Cancer
  • Pancreatic Cancer (Refractory)
  • Refractory Ovarian Cancer
  • Stage IIA Pancreatic Cancer
  • Stage IIIA Prostate Cancer
  • Stage IIIB Ovarian Cancer
  • Stage IV Prostate Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Olaparib
1
Glutaminase Inhibitor IPN60090
1
Cabozantinib S-malate

Study Objectives

5 Primary · 3 Secondary · Reporting Duration: Up to 6 months

Up to 28 days
Dose-limiting toxicities
Day 30
Change of the treatment regimen such as dose delay and dose reduction over time by dose level due to treatment-related adverse events
Incidence of >= grade 2 adverse events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
Incidence of adverse events and serious adverse events
Withdrawals from the study due to treatment-related adverse events will be documented
Up to 6 months
Clinical benefit
Objective responses
Predictive biomarkers

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Olaparib
1
Glutaminase Inhibitor IPN60090
1
Cabozantinib S-malate

Trial Design

1 Treatment Group

Treatment (TRPV6 calcium channel inhibitor SOR-C13)
1 of 1

Experimental Treatment

36 Total Participants · 1 Treatment Group

Primary Treatment: TRPV6 Calcium Channel Inhibitor SOR-C13 · No Placebo Group · Phase 1

Treatment (TRPV6 calcium channel inhibitor SOR-C13)
Drug
Experimental Group · 1 Intervention: TRPV6 Calcium Channel Inhibitor SOR-C13 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 6 months

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,098 Previous Clinical Trials
41,145,771 Total Patients Enrolled
2 Trials studying Stage IVA Prostate Cancer
400 Patients Enrolled for Stage IVA Prostate Cancer
M.D. Anderson Cancer CenterLead Sponsor
2,809 Previous Clinical Trials
1,790,475 Total Patients Enrolled
Siqing FuPrincipal InvestigatorM.D. Anderson Cancer Center
5 Previous Clinical Trials
561 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top